Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.

NCT01131195 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01131195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01131195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
July 19, 2010
Completion date
February 28, 2018
Enrollment
139 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer